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Evaluation of LOXL1 polymorphisms in exfoliation syndrome in
the Uygur population
    Mayinu, Xueyi Chen
Department of Ophthalmology, the First Affiliated Hospital of Xinjiang Medical University, Urumchi, Xinjiang Uygur Autonomous
Region, China
Purpose:  In  Uygur  populations,  exfoliation  syndrome  (XFS)  and  exfoliation  glaucoma  (XFG)  occurred  at  a  high
frequency. In this study, we evaluate the association profiles of the lysyl oxidase-like 1 (LOXL1) gene polymorphisms
with XFS in the Uygur population.
Methods: Sixty-four unrelated Uygur patients with XFS and 127 Uygur control subjects were included in this study.
Genotypes of the three single nucleotide polymorphisms (SNPs) of LOXL1 (rs1048661, rs2165241, and rs3825942) were
analyzed by direct sequencing, and a case-control association study was performed.
Results: The three SNPs were significantly associated with XFS and XFG individually. The G allele of rs1048661 (OR
[95%CI]: 1.92 [1.14–3.22]), G of rs3825942 (OR [95%CI]: 4.86 [2.02–11.68]), and T of rs2165241 (OR [95%CI]: 3.98
[2.54–6.25]) were risk alleles for the disorder. The genotypes GG for rs1048661 (OR [95%CI]: 2.13 [1.14–3.97]), GG
for rs3825942 (OR [95%CI]: 5.68 [2.28–14.17]), and TT for rs2165241 (OR [95%CI]: 6.13 [2.68–14.01]) were risk
genotypes for the disease. The haplotypes G-G for the SNPs rs1048661and rs3825942, G-T for the SNPs rs1048661 and
rs2165241, and SNPs rs3825942 and rs2165241 were found to be significantly associated with XFS/G. The haplotypes
G-G-T for the three SNPs were determined to be significantly associated with XFS/G. There were significant differences
of the allelic and genotypic proportion in different gender/age patients and controls for all three SNPs. T allele of rs2165241
and G of rs3825942 were risk alleles for the disorder in both the male and female groups. G allele of rs1048661 was a
risk allele for the disorder in the below 65-year-old group. T of rs2165241 was a risk allele for the disorder in both age
groups. G of rs3825942 was a risk allele for the disorder in the over 65-year-old group. The genotypes also showed
significant differences in the below 65-year-old group of rs1048661, both groups of rs2165241, and over 65-year-old
group of rs3825942.
Conclusions: LOXL1 is a susceptibility gene of XFS/XFG in Uygur populations. The risk alleles of rs1048661, rs3825942
and rs2165241 in Uygur subjects were found to be similar to those of populations in Iceland and the United States and
different from Han populations in China. The genotypic and allelic distributions of these SNPs are similar between XFS
and XFG.
Exfoliation syndrome (XFS) is an age-related, systemic,
elastic  microfibrillopathy  affecting  both  intraocularand
extraocular tissues [1]. The clinical features: white flake-like
material on the anterior lens surface, the pupillary border,
trabecular meshwork, zonula, ciliary body, and other anterior
segment structures etc were initially described by Lindberg in
1917 [2]. Exfoliation glaucoma (XFG) is characterized by
rapid progression, high resistance to medical therapy, and
poor prognosis. XFS can not only lead to severe chronic open-
angle glaucoma but also to acceleration of cataract formation,
lens  subluxation,  angle-closure  glaucoma,  and  severe
complications  at  the  time  of  cataract  extraction,  such  as
zonular dialysis, capsular rupture, and vitreous loss [2-5].
Especially in the Uygur populations in Xinjiang, because of
lack  of  medicines  and  awareness  of  the  disease,  XFS/G
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patients go to the hospital when they have almost lost their
visual acuity.
Epidemiological studies have shown that the prevalence
of XFS varies greatly among ethnic groups, with a prevalence
of 28% in Iceland, 20% in Finland, a little lower in Norway
and Switzerland [6], and 1.6~6.3% in north America and
western Europe. The highest incidence is in the Scandinavian
peninsula [7], while prevalence is 0% in the Greenland Inuit
population  [8,9].  It  can  affect  10%–20%  of  the  elderly
populations, so the elderly populations and glaucoma patients
have  a  higher  incidence  [10].  In  Asian  populations,  the
prevalence is 3.01%–6.28% in Indians aged over 40 years
[11,12], 3.4% in Japanese aged over 50 years [13], 0.4% in
Hong Kong Chinese aged over 60 years [14], 0.2% and 0.7%
in Singaporean Chinese aged over 40 and over 60 years [15],
3.3% in the Han people in China [16], 5.1% in the Kashi Uygur
[17], and 2.2% and 9.5% in the Kuche Uygur aged over 60
and 80 years, respectively [18].
According  to  studies  worldwide,  there  is  evidence
showing that genetic factors may play an important role in the
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1734pathogenesis of XFS [19]. Recently, Thorleifsson et al. [20]
performed a genome-wide association study and identified a
strong  association  of  XFG  with  three  single  nucleotide
polymorphisms  (SNPs)  in  the  lysyl  oxidase-like  1  gene
(LOXL1)  on  15q24.1.  They  identified  one  intronic  SNP
(rs2165241)  and  two  nonsynonymous  coding  SNPs
(rs3825942  and  rs1048661)  with  significant  disease
association  in  Icelandic  and  Swedish  individuals.  This
association was recently replicated in the midwestern United
States [21], Australian populations [22], Indian populations
[23],  Japanese  populations  [24],  and  Chinese  populations
[25]. XFS has a high prevalence in Uygur populations [17,
18]. Therefore it is logically important to perform a case-
control study using another ethnic population like the Uygur
Figure 1. Representative chromatograms displaying and the PCR
electrophoresis image for the SNP rs1048661. A, B, C: The three
different  genotypes  of  the  SNP  rs1048661.  D:  The  PCR
electrophoresis image for the SNP rs1048661.
minority in China who are different from the Han people, to
uncover the pathogenesis of XFS/G in Uygur patients.
Xinjiang lies in northwest China, bordering Gansu and
Qinghai provinces to the southeast and the Tibet Autonomous
Region to the south, and shares a 5,000-km border with eight
countries. It is the largest Chinese administrative division,
with a total population of nearly 21.56 million, and it is home
to 47 of China's 56 ethnic groups, such as Uygur (47.47%),
Han (37.58%), and Kazak (7.3%). We recruited our Uygur
case and control subjects from Kuche and Kashi, located in
the  south  of  the  Tianshan  Mountains,  where  the  urban
population is mainly Uygur.
METHODS
Study  subjects:  The  diagnostic  criterion  for  XFS  was  the
existence of exfoliation material on the anterior lens capsule
or on the pupil margin in either eye with dilation of the pupils.
Patients with intraocular pressure (IOP) of less than 21 mmHg
and no clinical evidence of glaucomatous optic neuropathy
were classified as XFS. XFG was diagnosed if the patient had
the above characteristics of exfoliation syndrome and all of
the following features: (1) IOP ≥22 mmHg in either eye; (2)
glaucomatous changes on the optic disc, defined as cup to disc
ratio >0.7 in either eye or an asymmetric cup to disc ratio of
>0.2  or  notching  of  the  disc  rim;  and  (3)  characteristic
glaucomatous visual field loss [26]. Patients with other causes
of secondary glaucoma, such as uveitis, pigment dispersion
syndrome,  and  iridocorneal  endothelial  syndrome,  were
excluded. The patients were recruited from Kashi and Kuche
Uygur people over 45 years of age. The controls were enrolled
by the following criteria: (1) no signs of XFS or XFG, (2) no
glaucomatous changes on the optic disc, (3) normal visual
field  and  intraocular  pressure,  (4)  no  family  history  of
glaucoma, and (5) no other eye diseases except mild refractive
errors. All study subjects were unrelated. All study subjects
received comprehensive ophthalmic examinations.
The  research  protocol  was  approved  by  the  Ethics
Committee  for  Human  Research  of  the  First  Affiliated
Hospital of Xinjiang Medical University, China. Informed
consent was obtained from all participants after explaining the
objective and nature of the study. The study was conducted in
accordance with the Declaration of Helsinki.
TABLE 1. PRIMER SEQUENCES FOR PCR FOR SNPS OF LOXL1.
Amplicon Primer sequences Size (bp)
rs1048661, rs3825942* F: 5′-ATTCGGCTTTGGCCAGGT-3′ 178
  R: 5′-GAACTGCTGCGGGTAGGA-3′  
rs2165241 F: 5′-CTCTAGGGCCCCTTGGAGAAT-3′ 321
  R: 5′-GGCCAGAGGTCTGCTAAGCAC-3′  
        Two sets of primers were used for PCR for the three SNPs. The asterisk indicates that the same set of primers was used for
         rs1048661 and rs3825942.
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1735Peripheral blood samples (2–3 ml) were collected from
each  subject  by  venipuncture  and  genomic  DNA  was
extracted  from  whole  blood  by  using  a  Genomic  DNA
Extraction  Kit,  (The  Beijing  Genomics  Institute,  Beijing,
China).  The  three  SNPs  (rs1048661,  rs3825942,  and
rs2165241) in the LOXL1 gene, in accordance with previous
reports, were amplified by PCR and directly sequenced [20,
23]. Two sets of primers were used for amplification by PCR
(Table 1). The PCR protocol was as follows: For rs2165241:
initial denaturation at 94 °C/5 min, followed by 10 cycles
(94 °C/30 s, 65–60 °C touchdown for 1 min with 0.5 °C
decrement, 72 °C/45 s), 30 cycles (94 °C/30 s, 60 °C/1 min,
72  °C/45  s),  and  a  final  extension  at  72  °C/1  min.  For
rs1048661 and rs3825942: initial denaturation at 94 °C for 5
min followed by denaturation at 94 °C for 30 s, annealing at
58–55 °C touchdown for 30 s with 0.5 °C decrement for the
first six cycles, extension at 72 °C for 45 s for 35 cycles, and
a final extension of 72 °C for 5 min.
Figure  2.  Representative
chromatograms displaying and the PCR
electrophoresis  image  for  the  SNP
rs2165241. A, B, C: The three different
genotypes  of  the  SNP  rs2165241.  D:
The PCR electrophoresis image for the
SNP rs2165241.
Figure  3.  Representative
chromatograms displaying and the PCR
electrophoresis  image  for  the  SNP
rs3825942. A, B, C: The three different
genotypes  of  the  SNP  rs3825942.  D:
The PCR electrophoresis image for the
SNP rs3825942
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1736Genotypes of the three LOXL1 SNPs were determined by
direct DNA sequencing, using BigDye Terminator v3.1 Kit
(Applied Biosystems, Foster City, CA) in a 3730XL capillary
sequencer  (Applied  Biosystems).  The  sequences  were
analyzed  by  sequencing  analysis  software  Chromas
(Technelysium  Pty  Ltd.,  Queensland,  Australia).
Representative chromatograms displaying these three SNPs
are provided in Figure 1 (rs1048661), Figure 2 (rs2165241),
and Figure 3 (rs3825942).
Statistical analysis: Statistical analysis was performed using
SPSS  v13.0  software  package  (SPSS  Inc.,  Chicago,  IL).
Hardy–Weinberg equilibrium (HWE) analysis was tested by
using the χ2 test in SAS/Genetics v9.1 (SAS Institute Inc.,
Cary,  NC).  The  comparison  of  allelic  and  genotypic
frequencies between the patient and control groups as well as
haplotype  association  analysis  were  performed  using  a
standard χ2 test with a p-value <0.05 considered statistically
significant.  Relative  risk  association  was  estimated  by
calculating  odds  ratios  (OR)  along  with  95%  confidence
intervals (CI).
RESULTS
A  total  of  64  Uygur  patients  with  exfoliation  syndrome,
including 7 cases of XFG, 4 cases of XFS with high IOP, and
53 cases of XFS without glaucoma, as well as 127 Uygur
control individuals, were recruited into this study. The age at
recruitment was 52–95 years (mean age 70.5±9.3 years) in the
patient group, and45–84 years (mean age 63.7±10.0 years) in
the control group. The gender distribution between the patient
and control groups was not significantly different (χ2=0.01,
p=0.97), with 41 (64.1%) males and 23 (35.9%) females in
the  patient  group  and  81  (63.8%)  males  and  46  (36.2%)
females  in  the  control  group.  The  clinical  features  of  the
patients are shown in Table 2. Eleven of the 64 XFG patients
had severe glaucoma and high IOP. Only one subject had
trabeculectomy and iridotomy, and two were treated with
medicine.
The genotype distribution of SNP rs1048661 (p=0.84 for
patients  and  p=0.68  for  controls),  rs3825942  (p=0.69  for
patients and p=0.12 for controls), and rs2165241 (p=0.37 for
patients  and  p=0.24  for  controls)  followed  the  HWE  in
patients and controls. Allelic association analysis showed that
there were significant differences in the allelic distributions
between the two groups for the three SNPs (Table 3). The
frequency of allele G of rs1048661 was higher in the patient
group than in the control group (p=0.013, OR=1.92, 95% CI:
1.14–3.22).  The  frequency  of  allele  T  of  rs2165241  was
significantly higher in the patient group than in the control
group  (p=0.000,  OR=3.98,  95%  CI:  2.54–6.25).  The
frequency of allele G of rs3825942 was significantly higher
in  the  patient  group  than  in  the  control  group  (p=0.000,
OR=4.86, 95% CI: 2.02–11.68). The genotypic frequencies
for  each  of  the  three  SNPs  were  also  compared  between
patients and controls (Table 3). The frequency of genotype
GG at SNP rs1048661 was higher in patients than in controls
(p=0.016, OR=2.13, 95% CI: 1.14–3.97), and the frequencies
of TT genotypes were not significantly different between the
two  groups.  The  frequency  of  genotype  TT  at  SNP
rs2165241 was significantly higher in the patient group than
in  the  control  group  (p=0.000,  OR=6.13,  95%  CI:  2.68–
14.01), and the frequency of CC genotypes was significantly
lower in the patients than in the controls. The frequency of
genotype GG at SNP rs3825942 was significantly higher in
the  patient  group  than  in  the  control  group  (p=0.000,
OR=5.68, 95% CI: 2.28–14.17), and the frequencies of AA
genotypes were not significantly different between the two
groups.
Haplotypes defined by the three SNPs were analyzed
(Table  4).  For  the  SNPs  rs1048661  and  rs3825942,  three
haplotypes  were  observed.  The  haplotype  G-G  (p=0.006,
OR=3.81,  95%  CI:  1.40–10.34)  was  identified  to  be
significantly  associated  with  the  patient  group.  For  SNPs
rs1048661 and rs2165241, four haplotypes were observed,
among which the haplotype G-T was significantly associated
TABLE 2. CLINICAL FEATURES OF THE PATIENTS WITH XFS/XFG.
  Total (n=64)
Clinical features XFG (n=7) XFS with high IOP (n=4) XFS (n=53)
Age at recruitment (mean±SD) 67.00±7.16 67.75±10.01 71.15±9.53
Range 58–76 60–81 52–95
Gender (male/female) 5/2 3/1 33/20
History of trabeculectomy n=1 n=0 n=0
History of laser trabeculoplasty n=0 n=0 n=0
History of laser iridotomy n=1 n=0 n=0
Treated with medicine n=2 n=0 n=0
        A total of 64 patients with exfoliation syndrome were recruited into this study, including 7 cases with XFG and 53 cases with
        XFS without glaucoma. Only one of the 7 XFG patients had trabeculectomy and laser iridotomy and 2 patients were treated
        with medicine.
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1737with the patient group (p=0.000, OR=3.66, 95% CI: 1.99–
6.90).  For  the  SNPs  rs3825942  and  rs2165241,  three
haplotypes were observed, with the haplotype G-T showing a
significantly  higher  frequency  in  the  patients  than  in  the
controls  (p=0.000,  OR=3.38,  95%  CI:  1.80–6.34).  The
haplotypes  for  the  three  SNPs  were  also  estimated.  The
haplotype G-G-T had a significantly higher frequency in the
patients than in the controls (p=0.000, OR=3.58, 95% CI:
1.90–6.76).
Allelic  and  genotypic  association  analysis  by  gender
showed that there are significant differences in the allelic and
genotypic distributions between the two groups for the three
SNPs  (Table  5).  The  G  allele  of  rs1048661  was  not
significantly different in either the male group or the female
group. At rs2165241 frequency of the T allele was higher in
male patients than in male controls (p=0.001, OR=2.51, 95%
CI: 1.44–4.39) and was significantly higher in female patients
than in female controls as well. (p=0.000, OR=9.75, 95% CI:
4.31–22.07). At rs3825942 frequency of the G allele was
higher  in  male  patients  than  in  male  controls  (p=0.005,
OR=3.79, 95% CI: 1.42–10.14) and was significantly higher
in female patients than in female controls (p=0.007, OR=10.2,
95% CI: 1.31–79.26). The genotypic frequencies for each of
the three SNPs were also compared between the patient and
control  groups  by  gender  (Table  5).  The  frequency  of
genotype  GG  at  SNP  rs1048661  was  not  significantly
different in either the male group or the female group. The
frequencies of genotype TT at SNP rs2165241 and GG at SNP
rs3825942 were significantly higher in the patients than in the
controls in both gender groups.
Allelic and genotypic association analysis in different
aged groups showed that there were significant differences in
TABLE 3. ALLELE AND GENOTYPE ASSOCIATION ANALYSIS FOR THE THREE SNPS OF LOXL1.
SNP XFS/XFG Control χ2 p value OR (95%CI)
rs1048661
Allele
G 104 (0.81) 176 (0.69) 6.22 0.013 1.92 (1.14–3.22)
T 24 (0.19) 78 (0.31)
Genotype
GG 42 (0.66) 60 (0.47) 5.78 0.016 2.13 (1.14–3.97)
GT 20 (0.31) 56 (0.44)      
TT 2 (0.03) 11 (0.09) 2.06 0.152 0.34 (0.07–1.58)
Total 64 127 6.37 0.041 NA
rs2165241
Allele
T 72 (0.56) 62 (0.24) 37.89 0.000 3.98 (2.54–6.25)
C 56 (0.44) 192 (0.76)
Genotype
TT 22 (0.34) 10 (0.08) 21.43 0.000 6.13 (2.68–14.01)
CT 28 (0.44) 42 (0.33)      
CC 14 (0.22) 75 (0.59) 23.64 0.000 0.19 (0.10–0.39)
Total 64 127 31.79 0.000 NA
rs3825942
Allele
G 122 (0.95) 205 (0.81) 14.73 0.000 4.86 (2.02–11.68)
A 6 (0.05) 49 (0.19)
Genotype
GG 58 (0.91) 80 (0.63) 16.21 0.000 5.68 (2.28–14.17)
GA 6 (0.09) 45 (0.35)      
AA 0 (0.00) 2 (0.02) 1.02 0.313 NA
Total 64 127 16.33 0.000 NA
        There were significant differences for the allelic proportion between the patient and control groups for all three SNPs. G allele
        of rs1048661, G of rs3825942, and T of rs2165241 were risk alleles for the disorder. The genotypes GG for rs1048661, GG for
        rs3825942, and TT for rs2165241 were risk genotypes for the disease. Total indicates the general test of association in the 2-
        by-3 table of disease-by-genotype. NA: not available. The asterisks indicates the OR values and p values derived from
        comparison  of  the  specific  genotype  with  all  the  others,  i.e.,  GG  versus  GT+TT  at  rs1048661,  TT  versus  CT+CT  at
        rs2165241.
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1738the allelic and genotypic distributions between the two groups
for the three SNPs (Table 6). At rs1048661 the frequency of
the G allele was higher in the patients than in the controls in
the below 65-year-old group (p=0.011, OR=3.86, 95% CI:
1.29–11.58). At rs2165241 the frequency of the T allele was
significantly higher in the patients than in the controls in both
aged groups. (≤65:p=0.000, OR=4.41, 95% CI: 2.09–9.30;
>65: p=0.000, OR=3.93, 95% CI: 2.18–7.10). At rs3825942
the frequency of the G allele was significantly higher in the
patients than in the controls in the over 65-year-old group.
(p=0.000,  OR=9.04,  95%  CI:  2.66–30.71).  The  genotypic
frequencies for each of the three SNPs were also compared
between  patients  and  controls  in  the  different  age  groups
(Table 6). The frequency of genotype GG at SNP rs1048661
was significantly higher in the patients than in the controls in
the below 65-year-old age group. The frequency of genotype
TT at SNP rs2165241 was significantly higher the patients
than  in  the  controls  in  both  aged  groups.  GG  at  SNP
rs3825942 was significantly higher in patients than in controls
in the over 65-year-old group.
DISCUSSION
This is the first study to show that the polymorphisms of
LOXL1 are associated with Uygur patients with XFS/G. These
results are important in understanding the role of  LOXL1
polymorphisms  in  the  pathogenesis  of  XFS/G  in  Uygur
patients. The association between LOXL1 and XFS/XFG in
the Han population has rarely been reported except in one
recent report from Beijing Tongren Eye Center [25]. In this
study, we recruited samples of XFS/XFG patients from Kuche
and Kashi which are inhabited mostly by Uygur people. Three
major LOXL1 SNPs were found to be significantly associated
with XFS/XFG, even though the sample size was small at 64.
Hence, the effect sizes of these SNPs in the Uygur population
were large, and 64 samples provided a good statistical power
to detect significant association. In Xinjiang, it is usually
difficult to recruit a large sample of XFS/XFG throughout the
TABLE 4. HAPLOTYPE ASSOCIATION ANALYSIS BETWEEN THE LOXL1 SNPS AND XFS/XFG.
Haplotype Proportion
χ2 p value
OR
(95%CI)       Case Control      
rs1048661 rs3825942            
T G   0.047 0.181 6.52 0.011 0.22 (0.06–0.77)
G G   0.922 0.756 7.66 0.006 3.81(1.40–10.34)
G A   0.031 0.063 0.86 0.353 0.48 (0.10–2.33)
Total         7.90 0.019 NA
rs1048661 rs2165241            
T C   0.031 0.157 6.65 0.010 0.17 (0.04–0.76)
G T   0.563 0.260 16.89 0.000 3.66 (1.99–6.90)
T T   0.016 0.024 0.13 0.716 0.66 (0.07–6.44)
G C   0.391 0.559 4.83 0.028 0.51 (0.27–0.93)
Total         19.21 0.000 NA
rs3825942 rs2165241            
G C   0.406 0.660 11.35 0.001 0.35 (0.19–0.65)
A T   0.016 0.008 0.25 0.619 2.00(0.12–32.51)
G T   0.563 0.280 15.00 0.000 3.38 (1.80–6.34)
A C   0.016 0.055 1.65 0.198 0.27 (0.03–2.26)
Total         16.06 0.001 NA
rs1048661 rs3825942 rs2165241          
T G C 0.031 0.157 6.65 0.010 0.17 (0.04–0.76)
G G C 0.375 0.504 2.85 0.092 0.59 (0.32–1.09)
G G T 0.547 0.252 16.25 0.000 3.58 (1.90–6.76)
T G T 0.016 0.024 0.13 0.716 0.66 (0.07–6.44)
G A C 0.016 0.055 1.65 0.198 0.27 (0.03–2.26)
G A T 0.016 0.008 0.25 0.619 2.00(0.12–32.51)
Total         19.93 0.001 NA
         The haplotypes G-G for the SNPs rs1048661 and rs3825942, G-T for the SNPs rs1048661 and rs2165241, and G-T for the SNPs
          rs3825942 and rs2165241 were identified to be significantly associated with XFS/G. The haplotype G-G-T for the three SNPs
          was identified to be significantly associated with XFS/G. Total indicates omnibus tests, while the others indicate the haplotype-
          specific tests. The OR values were obtained from comparison of each individual haplotype with all the other haplotypes, i.e.,
          T-G versus G-G + G-A for the SNPs rs1048661 and rs3825942, etc. NA: not available.
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1742autonomous region to ensure frequency matching because of
the long distance between cities.
The reason for the higher prevalence in Uygur individuals
than in Han individuals is still unknown [16-18]. In this study,
we found that all at-risk alleles and genotypes of the LOXL1
SNPs in the Uygur population are different from the Han
population but similar to Iceland [20] and the United States
[27].  Compared  to  the  frequency  of  the  G  allele  at
rs1048661, the frequency of the T allele at rs2165241 was
significantly  higher  in  the  patients  than  in  the  controls
(p=0.000, OR=3.98, 95% CI: 2.54–6.25), and the G allele at
rs3825942 was also significantly higher in the patients than in
the controls (p=0.000, OR=4.86, 95% CI: 2.02–11.68).
Such a discrepancy might not be fully explained by the
ethnic difference in the frequencies of the at-risk alleles of the
LOXL1  SNPs  (Table  7),  and  other  genetic  and/or
environmental factors might be involved in the development
of the disorder.
In the present study, alleles and genotypes were also
significantly  associated  with  XFS/XFG  subjects  between
different gender and age groups. The alleles and genotypes in
rs1048661 were not statistically significant between gender
groups,  as  opposed  to  rs2165241  and  rs3825942,  which
showed higher OR and 95%CI in the female group than in the
male group. At rs1048661 the frequency of the G allele was
higher in the patients than in the controls in the below 65-year-
old group. At rs2165241 the frequency of the T allele was
significantly higher in the patients than in the controls in both
age groups. At rs3825942 the frequency of the G allele was
significantly higher in the patients than in the controls in the
over 65-year-old group. Therefore, gender and age might also
play an important role in the pathogenesis of XFS/G in Uygur
patients.
Although  this  is  our  first  step  in  researching  the
polymorphisms of LOXL1 in Uygur patients, the role of this
SNP in pathogenesis of the disorder in Uygur patients needs
to  be  studied  further,  and  further  investigations  are  also
needed  to  determine  additional  genetic  or  environmental
factors modifying the development of this disorder.
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